Boulder-based Ambrosia Biosciences secured $100 million in oversubscribed Series B funding to advance its oral small molecule GLP-1 through clinical trials, led by Blue Owl, Redmile, and Deep Track Capital.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.